Biest 50/50 is a compounded hormone cream or gel that contains two types of estrogen in equal parts: 50% estriol and 50% estradiol. It’s one of several “biestrogen” formulations used to treat menopause symptoms like hot flashes, night sweats, and vaginal dryness. Unlike FDA-approved hormone therapies, Biest 50/50 is custom-made by compounding pharmacies, which means it isn’t standardized or regulated the same way as conventional medications.
What the 50/50 Ratio Means
The two numbers refer to the proportion of each estrogen in the formula. In Biest 50/50, half the estrogen content is estriol and half is estradiol. Your body naturally produces both of these hormones, but they differ in potency. Estradiol is the stronger of the two and is the primary estrogen your ovaries produce during your reproductive years. Estriol is much weaker, roughly 80 times less potent than estradiol, and is produced in large quantities mainly during pregnancy.
The 50/50 ratio is not the only version available. A more common formulation is Biest 80/20, which contains 80% estriol and 20% estradiol. The idea behind using more estriol is that it may provide symptom relief with a gentler estrogenic effect. A 50/50 blend delivers a relatively higher dose of the potent estradiol compared to the 80/20 version, which some practitioners prescribe when a patient needs stronger symptom control.
How Biest Is Used
Biest is typically applied as a topical cream, though it can also come in other forms like gels or troches (small lozenges that dissolve under the tongue). The hormones in these formulations are derived from plant sources, usually wild yam, and then synthesized in a lab to be structurally identical to the estrogen your body produces. This is what “bioidentical” means: the molecular structure matches human hormones.
Practitioners prescribe Biest primarily for menopausal and perimenopausal symptoms. These include hot flashes, night sweats, vaginal dryness, sleep disruption, and mood changes. Some evidence suggests that biestrogen therapy can reduce the frequency and severity of hot flashes and night sweats by up to 80%. It may also help protect against bone loss during menopause, support vaginal lubrication, and stabilize mood.
Compounded vs. FDA-Approved Hormones
This is the most important distinction to understand about Biest. It is not an FDA-approved drug. It’s made by compounding pharmacies, which mix custom formulations based on a prescriber’s instructions. FDA-approved bioidentical estrogen products do exist (patches, pills, and creams containing estradiol), but Biest specifically is not among them.
That matters for several practical reasons. Compounded medications don’t go through the same testing for potency, purity, or consistency that FDA-approved drugs require. Independent testing has confirmed that the amount of active hormone in compounded preparations can vary significantly from one dose to the next within the same prescription. There are also no requirements for adverse event reporting with compounded drugs, which makes it harder to track safety over time.
The American College of Obstetricians and Gynecologists has stated that compounded bioidentical hormone therapy should not be routinely prescribed when FDA-approved formulations are available. The organization has also noted that while compounding pharmacies often market these products as “natural” and therefore safer, evidence to support those claims is lacking. The bioidentical estradiol in a compounded Biest cream is chemically the same molecule found in FDA-approved estradiol products, so the “natural” distinction is largely a marketing one.
Side Effects and Risks
Because Biest contains estrogen, it carries the same general risks as any estrogen-based hormone therapy. Common side effects include headaches, breast tenderness, nausea, bloating, weight changes, mood shifts, and irregular vaginal bleeding. These often lessen after the first few months of use.
The more serious risks associated with estrogen therapy include blood clots in the legs or lungs, stroke, and an increased risk of breast cancer, particularly when estrogen is combined with a progestin (which is necessary for anyone who still has a uterus, to protect against endometrial cancer). Long-term use may also be associated with an increased risk of cognitive decline. Smoking while using estrogen therapy raises the risk of blood clots and stroke further.
These risks apply to estrogen therapy broadly, not just to compounded versions. However, the inconsistent dosing that can occur with compounded products adds a layer of unpredictability. You could receive more or less hormone than intended in any given dose, which makes it harder to manage side effects or calibrate the right amount for your symptoms.
Why Some People Choose the 50/50 Ratio
Practitioners who prescribe Biest 50/50 over the more common 80/20 ratio typically do so because a patient needs stronger symptom relief. Since estradiol is the more potent estrogen, increasing its proportion in the blend delivers a more robust estrogenic effect. Someone experiencing severe hot flashes or significant vaginal atrophy that hasn’t responded to a gentler formulation might be switched to a 50/50 ratio.
Some proponents also argue that estriol, as the weaker estrogen, may have a protective effect on breast tissue compared to estradiol alone. This theory is one reason biestrogen formulations exist in the first place, rather than simply prescribing estradiol by itself. However, large-scale clinical trials confirming this protective effect are limited, and no major medical organization currently endorses estriol as a safer alternative to estradiol based on existing evidence.
What to Know Before Starting Biest
If you’re considering Biest 50/50, the key question isn’t whether bioidentical hormones work for menopause symptoms. They do, and the estradiol in Biest is the same molecule used in FDA-approved products. The real question is whether a compounded version offers advantages over a standardized, regulated one.
There are legitimate reasons someone might need a compounded formulation: an allergy to an inactive ingredient in an approved product, a need for a dose or delivery method not commercially available, or difficulty tolerating standard options. Outside those situations, the variability in compounded products is a genuine drawback. You’re getting the same active hormone but with less consistency and no formal safety monitoring.
If your provider recommends Biest, ask why a compounded version is preferred over an FDA-approved bioidentical option. Understanding the reasoning helps you weigh the tradeoffs between customization and the quality controls that come with regulated medications.